|
Age (years, median, range)
|
50 (25–75)
|
54 (25–74)
|
45 (26–75)
|
0.2268
|
|
Surgical FIGO stage
| | | |
0.0745
|
|
Stage 3 (n, %)
|
175 (86.6%)
|
98 (85.2%)
|
75 (76.5%)
| |
|
Stage 4 (n, %)
|
27 (13.4%)
|
17 (14.8%)
|
23 (23.5%)
| |
|
Histology
| | | |
0.7059
|
|
Serous (n, %)
|
166 (82.2%)
|
89 (77.4%)
|
75 (76.5%)
| |
|
Endometrioid (n, %)
|
22 (10.9%)
|
15 (13.0%)
|
11 (11.2%)
| |
|
Mixed (n, %)
|
6 (3.0%)
|
5 (4.3%)
|
4 (4.1%)
| |
|
Clear cell (n, %)
|
5 (2.5%)
|
4 (3.5%)
|
2 (2.0%)
| |
|
Other (n, %)
|
3 (1.5%)
|
2 (1.7%)
|
5 (5.1%)
| |
|
Cytoreduction
| | | |
0.0793
|
|
Optimal (n, %)
|
177 (87.6%)
|
97 (84.3%)
|
76 (77.6%)
| |
|
Sub-optimal (n, %)
|
25 (12.4%)
|
18 (15.7%)
|
22 (22.4%)
| |
|
Days to flatus (median, range)
|
7 (4–10)
|
7 (4–10)
|
6.5 (4–10)
|
0.7305
|
|
Days of hospitalization (median, range)
|
12 (5–20)
|
13 (5–20)
|
12.5 (5–20)
|
0.673
|
|
Serum albumin (g/L) (median, range)
|
4.9 (3–6)
|
3.3 (1–5.9)
|
2.45 (1–4.8)
|
< 0.001
|
|
BMI at admission (median, range)
|
27.9 (16.1–40)
|
22.8 (16.1–39.6)
|
20.15 (16–29.3)
|
< 0.001
|
|
BMI after surgery (median, range)
|
25.9 (15.2–35)
|
23.8 (15.2–30.9)
|
21.05 (16–26)
|
< 0.001
|
|
NRI at admission (median, range)
|
100 (97.5–108)
|
92 (83.5–99.9)
|
80.15 (75.5–91.4)
|
< 0.001
|
|
PFS (days, median, range)
|
108 (20–200)
|
90 (10–179)
|
67.5 (10–120)
|
< 0.001
|
|
OS (days, median, range)
|
240.5 (102–396)
|
227 (100–357)
|
207.5 (983–298)
|
< 0.001
|
